Literature DB >> 10600481

Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan.

P Tapanadechopone1, J R Hassell, B Rigatti, J R Couchman.   

Abstract

Perlecan, the predominant basement membrane proteoglycan, has previously been shown to contain glycosaminoglycans attached at serine residues, numbers 65, 71, and 76, in domain I. However, the C-terminal domains IV and V of this molecule may also be substituted with glycosaminoglycan chains, but the exact substitution sites were not identified. The amino acid sequence of mouse perlecan reveals many ser-gly sequences in these domains that are possible sites for glycosaminoglycan substitution. We expressed recombinant domain IV and/or V of mouse perlecan in COS-7 cells and analyzed glycosaminoglycan substitution. Both heparan sulfate and chondroitin sulfate chains could be detected on recombinant domain V. One site, ser-gly-glu (serine residue 3593), toward the C-terminal region of domain V is a substitution site for heparan sulfate. When this sequence was absent, chondroitin/dermatan sulfate substitution was deleted, and the likely site for this galactosaminoglycan substitution was ser-gly-ala-gly (serine residue 3250) on domain V. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600481     DOI: 10.1006/bbrc.1999.1714

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.

Authors:  Karin Tran-Lundmark; Phan-Kiet Tran; Gabrielle Paulsson-Berne; Vincent Fridén; Raija Soininen; Karl Tryggvason; Thomas N Wight; Michael G Kinsella; Jan Borén; Ulf Hedin
Journal:  Circ Res       Date:  2008-07-03       Impact factor: 17.367

2.  Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing.

Authors:  Moonsun Jung; Megan S Lord; Bill Cheng; J Guy Lyons; Hatem Alkhouri; J Margaret Hughes; Simon J McCarthy; Renato V Iozzo; John M Whitelock
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

Review 3.  Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.

Authors:  Mary C Farach-Carson; Curtis R Warren; Daniel A Harrington; Daniel D Carson
Journal:  Matrix Biol       Date:  2013-08-31       Impact factor: 11.583

4.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

Review 5.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

6.  Collagen type IV and Perlecan exhibit dynamic localization in the Allantoic Core Domain, a putative stem cell niche in the murine allantois.

Authors:  Maria M Mikedis; Karen M Downs
Journal:  Dev Dyn       Date:  2009-12       Impact factor: 3.780

7.  The core protein of growth plate perlecan binds FGF-18 and alters its mitogenic effect on chondrocytes.

Authors:  Simone M-L Smith; Leigh A West; John R Hassell
Journal:  Arch Biochem Biophys       Date:  2007-10-22       Impact factor: 4.013

8.  Dynamic expression patterns of ECM molecules in the developing mouse olfactory pathway.

Authors:  Elaine L Shay; Charles A Greer; Helen B Treloar
Journal:  Dev Dyn       Date:  2008-07       Impact factor: 3.780

9.  Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney.

Authors:  Maarit Rossi; Hiroyuki Morita; Raija Sormunen; Sari Airenne; Marjut Kreivi; Ling Wang; Naomi Fukai; Bjorn R Olsen; Karl Tryggvason; Raija Soininen
Journal:  EMBO J       Date:  2003-01-15       Impact factor: 11.598

10.  Comparative immunolocalisation of fibrillin-1 and perlecan in the human foetal, and HS-deficient hspg2 exon 3 null mutant mouse intervertebral disc.

Authors:  Anthony J Hayes; Susan M Smith; James Melrose
Journal:  Histochem Cell Biol       Date:  2012-10-27       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.